ArticleInternational journal of chronic obstructive pulmonary disease2025
Serum IL-33/ST2 Axis Expression in Acute Exacerbations of COPD: Correlation with Pulmonary Function.
Article in International journal of chronic obstructive pulmonary disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Beyond Blood Eosinophils: Target-Tier Heterogeneity and Patient Enrichment in COPD Type 2 Inflammation.Journal of inflammation research · 2026Review
- Beyond inhaled medications: precision medicine and biologic therapies targeting the IL-33/TSLP/type 2 axis in COPD.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic obstructive pulmonary disease (COPD) exacerbations significantly contribute to morbidity and mortality. Identifying biomarkers linked to disease severity can enhance COPD management. This study investigates the relationship between serum IL-33 and ST2 levels and reduced pulmonary function during acute exacerbations of COPD (AECOPD). Methods: We conducted a cross-sectional analysis of 194 AECOPD patients assessing IL-33 and ST2 serum levels and their associations with pulmonary function parameters. Patients were stratified into subgroups by age, gender, and the presence of pulmonary hypertension (PH) to explore differential biomarker impacts. Results: IL-33 and ST2 levels demonstrated significant inverse correlations with FEV1% predicted (IL-33: r = -0.561, ST2: r = -0.545, p < 0.001) and the FEV1/FVC ratio. Logistic regression confirmed IL-33 (OR = 1.32, p < 0.001) and ST2 (OR = 1.29, p < 0.001) was associated with reduced pulmonary function. Subgroup analysis revealed more pronounced associations in older patients (≥ 67 years), males, and those with PH. Conclusion: IL-33 and ST2 are promising biomarkers for identifying individuals at higher risk of reduced pulmonary function during AECOPD. Their utility is particularly significant in specific demographics, emphasizing the need for integrated biomarker-guided COPD management strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.